Visualitza per autor "Scambia, Giovanni"
Ara mostrant els elements 1-6 d 6
-
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
Capoluongo, Ettore Domenico; Pellegrino, B.; Califano, D.; Beltrame, L.; Serra Elizalde, Violeta; Llop Guevara, Alba; Scambia, Giovanni (Elsevier, 2022-10) -
Dostarlimab: From preclinical investigation to drug approval and future directions
Cicala, Carlo Maria; Musacchio, lucia; Scambia, Giovanni; Lorusso, Domenica (Taylor & Francis, 2023) -
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
Selle, Frédéric; Bernard, Asselain; Marmé, Frederik; Lindemann, Kristina; PUJADE-LAURAINE, Eric; Scambia, Giovanni; OAKNIN, ANA (Elsevier, 2023-12) -
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
DiSilvestro, Paul; Kim, Byoung-Gie; Oaknin Benzaquen, Ana Mazaltob; Scambia, Giovanni; Banerjee, Susana; Colombo, Nicoletta (American Society of Clinical Oncology, 2023-01-20) -
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
Moore, Kathleen N; Oza, Amit M.; Oaknin Benzaquen, Ana Mazaltob; Lorusso, Domenica; Scambia, Giovanni; Colombo, Nicoletta (Elsevier, 2021-06) -
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
Moore, Kathleen N; Oaknin Benzaquen, Ana Mazaltob; Friedlander, Michael; Lisyanskaya, Alla; Scambia, Giovanni; Colombo, Nicoletta (Elsevier, 2021-10)